Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 1, 2002, Pages 6-8

  Booser, Daniel J ^a   Esteva, Francisco J ^a   Rivera, Edgardo ^a   Valero, Vicente ^a   Esparza Guerra, Laura ^a   Priebe, Waldemar ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Annamycin; Anthracycline; Resistant breast cancer

Indexed keywords

ANNAMYCIN; DOXORUBICIN; LIPOSOME;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 0036308763     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0464-0     Document Type: Article

References (3)

1. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach
2. Phase I study of liposomal annamycin
3. Preclinical toxicity of liposome-incorporated annamycin: Selective bone marrow toxicity with lack of cardiotoxicity